Affymetrix, Inc. (NASDAQ:AFFX)
CAPS Rating:
Engaged in the development, manufacture, sale and service of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets and create tools that advances the understanding of the molecular basis of life.
RSS Headlines
Fool UK
Recs
Deeply oversold and about to return to profitability so the stock should get above $6 in the next 3-12 months.